Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$4.15B |
$43.14
+4.03%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.13B |
$23.70
-1.04%
|
|
VKTX
Viking Therapeutics, Inc.
VK2735 is a peptide-based dual GLP-1/GIP receptor agonist, the company's lead therapeutic.
|
$4.08B |
$36.30
+2.37%
|
|
ACLX
Arcellx, Inc.
Company's lead products are CAR-T cell therapies within oncology; direct product category is cell therapy.
|
$4.06B |
$73.24
+0.33%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$4.04B |
$206.15
+1.29%
|
|
LNTH
Lantheus Holdings, Inc.
Directly produces radiopharmaceutical imaging agents and related therapies (e.g., PYLARIFY, DEFINITY) and maintains an expanding pipeline in this modality.
|
$3.99B |
$58.73
-0.57%
|
|
PRAX
Praxis Precision Medicines, Inc.
Solidus platform develops antisense oligonucleotide (ASO) therapeutics (e.g., elsunersen).
|
$3.97B |
$188.85
+2.50%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Main revenue driver is generic drugs in Affordable Medicines.
|
$3.93B |
$12.53
+0.68%
|
|
CNTA
Centessa Pharmaceuticals plc
ORX750 is an orally administered, high-potency orexin receptor 2 (OX2R) agonist, fitting the 'Oral Small Molecule Therapeutics' category.
|
$3.89B |
$28.97
+0.03%
|
|
NAMS
NewAmsterdam Pharma Company N.V.
Lead asset obicetrapib is an oral, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$3.83B |
$41.47
+2.55%
|
|
BLTE
Belite Bio, Inc
Lead product Tinlarebant is an ophthalmic drug targeting retinal diseases (STGD1/GA).
|
$3.78B |
$128.21
+0.32%
|
|
VCYT
Veracyte, Inc.
Tests function as companion diagnostics to identify patients most likely to benefit from specific therapies.
|
$3.75B |
$47.77
-3.26%
|
|
ARQT
Arcutis Biotherapeutics, Inc.
Arcutis' ZORYVE topical PDE4 inhibitor targets inflammatory dermatologic conditions, aligning with Immunology Therapeutics.
|
$3.71B |
$30.95
+0.72%
|
|
MIRM
Mirum Pharmaceuticals, Inc.
Core business includes liver disease therapeutics, with LIVMARLI and CTEXLI and acquired bile acid medications.
|
$3.67B |
$73.17
+1.96%
|
|
SWTX
SpringWorks Therapeutics, Inc.
SpringWorks specializes in oncology therapies using targeted small-molecule modalities (nirogacestat and mirdametinib).
|
$3.52B |
$46.99
|
|
XENE
Xenon Pharmaceuticals Inc.
Xenon's lead asset XEN1101 is a selective Kv7 potassium channel opener, mapping to Ion Channel Modulators.
|
$3.43B |
$44.47
+1.21%
|
|
CGON
CG Oncology, Inc. Common stock
CG Oncology is a biotech company focused on oncology therapies, with cretostimogene grenadenorepvec representing an oncology product in late-stage development.
|
$3.42B |
$44.84
-1.46%
|
|
TARS
Tarsus Pharmaceuticals, Inc.
XDEMVY is an FDA-approved ophthalmic drug and core commercial product for Demodex blepharitis.
|
$3.40B |
$80.53
+2.09%
|
|
UUUU
Energy Fuels Inc.
Radium/radioisotope recovery plans for targeted alpha therapy isotopes (radiopharmaceuticals).
|
$3.31B |
$14.38
-0.86%
|
|
IRON
Disc Medicine, Inc.
Disc Medicine concentrates on rare hematologic diseases (e.g., EPP, Diamond-Blackfan anemia) by targeting iron and heme pathways, with a pipeline centered on rare-disease indications.
|
$3.26B |
$93.73
+1.30%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
Ultragenyx is a rare-disease focused biotech company with approved therapies and a pipeline centered on ultra-rare diseases.
|
$3.25B |
$33.75
+0.67%
|
|
TVTX
Travere Therapeutics, Inc.
Lead product FILSPARI (sparsentan) is an oral small molecule therapeutic for IgA nephropathy, representing the core commercial and product-focused program.
|
$3.23B |
$36.27
+0.72%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
Kiniksa's core clinical focus centers on immunology therapeutics, driven by ARCALYST and its inflammatory disease pipeline.
|
$3.15B |
$42.53
-0.42%
|
|
IDYA
IDEAYA Biosciences, Inc.
IDEAYA is a biotechnology company focused on precision oncology therapies (synthetic lethality and ADCs).
|
$3.14B |
$35.89
+1.13%
|
|
FOLD
Amicus Therapeutics, Inc.
Amicus Therapeutics’s marketed products address rare genetic diseases (Fabry and Pompe) and its pipeline includes a rare-kidney disease program (DMX-200 for FSGS), placing it in Biotech - Rare Diseases.
|
$3.09B |
$10.02
+1.47%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$3.01B |
$21.17
+1.78%
|
|
ADPT
Adaptive Biotechnologies Corporation
Antibody Discovery Platform cited as part of Immune Medicine R&D capabilities.
|
$3.00B |
$19.73
-2.93%
|
|
PBH
Prestige Consumer Healthcare Inc.
Fleet and other PBH brands address digestive health with OTC solutions.
|
$2.93B |
$59.56
+0.93%
|
|
MLYS
Mineralys Therapeutics, Inc.
The company is pursuing a cardiovascular hypertension therapy, placing Mineralys under the Cardiovascular Drugs category.
|
$2.87B |
$43.37
+2.76%
|
|
CPRX
Catalyst Pharmaceuticals, Inc.
CPRX directly develops and sells oral small molecule therapeutics (FIRDAPSE, AGAMREE, FYCOMPA).
|
$2.87B |
$23.43
-0.68%
|
|
DNLI
Denali Therapeutics Inc.
DNL310 and DNL126 are recombinant enzymes delivered via Denali's TransportVehicle platform, representing its core product categories.
|
$2.84B |
$19.40
+1.41%
|
Showing page 5 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
